Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Disparities in Bladder Cancer Treatment and Survival Amongst Elderly Patients with a Pre-existing Mental Illness.

Sathianathen NJ, Fan Y, Jarosek SL, Konety I, Weight CJ, Vinogradov S, Konety BR.

Eur Urol Focus. 2019 Feb 20. pii: S2405-4569(19)30027-6. doi: 10.1016/j.euf.2019.02.007. [Epub ahead of print]

PMID:
30797737
2.

Penetrating Colon Trauma Outcomes in Black and White Males.

Skube SJ, Lindgren B, Fan Y, Jarosek S, Melton GB, McGonigal MD, Kwaan MR.

Am J Prev Med. 2018 Nov;55(5S1):S5-S13. doi: 10.1016/j.amepre.2018.05.007.

3.

Racial and Geographic Disparities in Hepatocellular Carcinoma Outcomes.

Franco RA, Fan Y, Jarosek S, Bae S, Galbraith J.

Am J Prev Med. 2018 Nov;55(5S1):S40-S48. doi: 10.1016/j.amepre.2018.05.030.

4.

Health System Affiliation and 30-Day Readmission After Heart Attack in Black Men.

Williams JH, Jarosek S, Carroll N, Fan Y, Hall AG.

Am J Prev Med. 2018 Nov;55(5S1):S22-S30. doi: 10.1016/j.amepre.2018.05.021.

5.

Racial Disparities in Surgical Outcomes Among Males Following Major Urologic Cancer Surgery.

Sathianathen NJ, Jarosek SL, Fan Y, Krishna SR, Konety BR.

Am J Prev Med. 2018 Nov;55(5S1):S14-S21. doi: 10.1016/j.amepre.2018.05.012.

6.

Increased Surgical Complications in Smokers Undergoing Radical Cystectomy.

Sathianathen NJ, Weight CJ, Jarosek SL, Konety BR.

Bladder Cancer. 2018 Oct 29;4(4):403-409. doi: 10.3233/BLC-180185.

7.

Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study.

Sathianathen NJ, Fan Y, Jarosek SL, Lawrentschuk NL, Konety BR.

Urol Oncol. 2018 Jul;36(7):338.e13-338.e17. doi: 10.1016/j.urolonc.2018.03.020. Epub 2018 May 3.

PMID:
29731413
8.

A Simplified Frailty Index to Predict Outcomes After Radical Cystectomy.

Sathianathen NJ, Jarosek S, Lawrentschuk N, Bolton D, Konety BR.

Eur Urol Focus. 2018 Jan 20. pii: S2405-4569(18)30002-6. doi: 10.1016/j.euf.2017.12.011. [Epub ahead of print]

PMID:
29366857
9.

Decreased Use of Sphincter-Preserving Procedures Among African Americans with Rectal Cancer.

Arsoniadis EG, Fan Y, Jarosek S, Gaertner WB, Melton GB, Madoff RD, Kwaan MR.

Ann Surg Oncol. 2018 Mar;25(3):720-728. doi: 10.1245/s10434-017-6306-4. Epub 2017 Dec 27.

PMID:
29282601
10.

Urethral Rest with Suprapubic Cystostomy for Obliterative or Nearly Obliterative Urethral Strictures: Urethrographic Changes and Implications for Management.

Moncrief T, Gor R, Goldfarb RA, Jarosek S, Elliott SP; Trauma and Urologic Reconstruction Network of Surgeons.

J Urol. 2018 May;199(5):1289-1295. doi: 10.1016/j.juro.2017.11.110. Epub 2017 Dec 6.

PMID:
29221931
11.

Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments.

Bolch CA, Chu H, Jarosek S, Cole SR, Elliott S, Virnig B.

BMC Med Res Methodol. 2017 Jul 10;17(1):93. doi: 10.1186/s12874-017-0367-8.

12.

Long-term Risk of Urinary Adverse Events in Curatively Treated Patients With Rectal Cancer: A Population-Based Analysis.

Kwaan MR, Fan Y, Jarosek S, Elliott SP.

Dis Colon Rectum. 2017 Jul;60(7):682-690. doi: 10.1097/DCR.0000000000000788.

PMID:
28594717
13.

The burden of chronic ureteral stenting in cervical cancer survivors.

Goldfarb RA, Fan Y, Jarosek S, Elliott SP.

Int Braz J Urol. 2017 Jan-Feb;43(1):104-111. doi: 10.1590/S1677-5538.IBJU.2016.0667.

14.

Racial Disparities in Active Surveillance for Prostate Cancer.

Krishna S, Fan Y, Jarosek S, Adejoro O, Chamie K, Konety B.

J Urol. 2017 Feb;197(2):342-349. doi: 10.1016/j.juro.2016.08.104. Epub 2016 Sep 3.

PMID:
27596691
15.

Place of Death of Individuals with Terminal Cancer: New Insights from Medicare Hospice Place-of-Service Codes.

Jarosek SL, Shippee TP, Virnig BA.

J Am Geriatr Soc. 2016 Sep;64(9):1815-22. doi: 10.1111/jgs.14269. Epub 2016 Aug 18.

PMID:
27534517
16.

Time Course and Accumulated Risk of Severe Urinary Adverse Events After High- Versus Low-Dose-Rate Prostate Brachytherapy With or Without External Beam Radiation Therapy.

Tward JD, Jarosek S, Chu H, Thorpe C, Shrieve DC, Elliott S.

Int J Radiat Oncol Biol Phys. 2016 Aug 1;95(5):1443-1453. doi: 10.1016/j.ijrobp.2016.03.047. Epub 2016 Apr 7.

PMID:
27325475
17.

Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.

Zabell JR, Adejoro O, Jarosek SL, Elliott SP, Konety BR.

World J Urol. 2016 Oct;34(10):1397-403. doi: 10.1007/s00345-016-1790-x. Epub 2016 Feb 25.

PMID:
26914817
18.

The Patient Burden of Bladder Outlet Obstruction after Prostate Cancer Treatment.

Liberman D, Jarosek S, Virnig BA, Chu H, Elliott SP.

J Urol. 2016 May;195(5):1459-1463. doi: 10.1016/j.juro.2015.11.072. Epub 2015 Dec 9.

PMID:
26682759
19.

Propensity-Weighted Comparison of Long-Term Risk of Urinary Adverse Events in Elderly Women Treated For Cervical Cancer.

Elliott SP, Fan Y, Jarosek S, Chu H, Downs L, Dusenbery K, Geller MA, Virnig BA.

Int J Radiat Oncol Biol Phys. 2015 Jul 1;92(3):586-93. doi: 10.1016/j.ijrobp.2015.02.025. Epub 2015 Apr 16.

PMID:
25890845
20.

Propensity-weighted long-term risk of urinary adverse events after prostate cancer surgery, radiation, or both.

Jarosek SL, Virnig BA, Chu H, Elliott SP.

Eur Urol. 2015 Feb;67(2):273-80. doi: 10.1016/j.eururo.2014.08.061. Epub 2014 Sep 10.

PMID:
25217421

Supplemental Content

Loading ...
Support Center